

CROSSJECT receives €2.9M from Bpifrance as part of the PIAVE financing

16 March 2017

CROSSJECT, (ISIN: FRO011716265; Mnemo: ALCJ), a specialty pharma developing a portfolio of New Therapeutic Entities for emergency auto-injection, has announced the payment of €2.9M as part of the *Programme des Investissements d’Avenir* (PIAVE) financing granted by Bpifrance.

This milestone payment is part of the PIAVE financing, amounting to a total of €6.7M and announced in November 2015.

Bpifrance has validated the advances made by CROSSJECT on the industrial project PARC® (preparatory pharmaceutical operations of tubes) and in the development of the drug Zeneo® Midazolam (epileptic seizures). The authorization to carry out the bioequivalence study, announced by Crossject on 6th March, is also part of it.

Patrick Alexandre, Chairman of Crossject, stated: *“Crossject is proceeding as planned with its innovation strategy on emergency products, of which Zeneo® Midazolam is the frontrunner. The support of Bpifrance through the program PIAVE has been added to other resources which are allowing us to speed up development, in particular the ongoing capital increase with priority subscription rights maintained.”*

Contacts

CROSSJECT

Patrick Alexandre
info@CROSSJECT.com

Investor relations

Actifin

Benjamin Lehari +33 (0)1 56 88 11 25
blehari@actifin.fr

Press relations

Citigate Dewe Rogerson

Laurence Bault +33 (0)1 53 32 84 78
laurence.bault@citigate.fr

About CROSSJECT • www.CROSSJECT.com

CROSSJECT (ISIN: FRO011716265; Mnemo: ALCJ) is a specialty pharma developing and conceiving a portfolio of drug candidates for emergency situations (overdoses, acute migraines, epilepsy, temporary paralysis, anaphylactic shocks, etc.). With Zeneo[®], its patented needle-free injection system, CROSSJECT provides efficiency to emergency situations by allowing simple drug self-administration. CROSSJECT is listed on Alternext (Euronext Paris) since February 2014



Follow us on Twitter: @Crossject_

Disclaimer

Some of the statements contained in this press release constitute forward-looking statements. These statements constitute either expectations or goals and shall not be considered as future results or any other performance indicators. These statements involve risks and uncertainties, out of control of the company in certain cases, especially during a R&D process. A detailed description of these risks and uncertainties is to be found in the Document de Base of the company, available on its website (www.crossject.com)